Document is current
Any future updates will be listed below
-
Authors
Cholujova, Danka
Csicsatkova, Nikoleta
Valuskova, Zuzana
Suroviakova, Katarina
Marinkovicova, Maria Elisabeth
Strizova, Anna
Sedlak, Jan
Jakubikova, Jana https://orcid.org/0000-0003-2593-569X
-
Funding
Funding for this research was provided by:
Vedecká Grantová Agentúra MŠVVaŠ SR a SAV (VEGA 2/0088/23)
Vedecká Grantová Agentúra MŠVVaŠ SR a SAV (VEGA 2/0087/23)
Agentúra na Podporu Výskumu a Vývoja (APVV-20-0183)
Agentúra na Podporu Výskumu a Vývoja (APVV-21-0215)
Agentúra na Podporu Výskumu a Vývoja (APVV-19-0212)
Agentúra na Podporu Výskumu a Vývoja (APVV-23-0482)
Agentúra na Podporu Výskumu a Vývoja (APVV-24-0471)
NextGenerationEU project (No.09I03-03-V04-00451)
NextGenerationEU project (No. 09I03-03-V02-00031)
Research & Innovation Operational Programme funded by the ERDF (ITMS project code 313021T081)
Slovak Academy of Sciences
- License Information
-
More Information
Article History
Received: 25 June 2025
Revised: 16 January 2026
Accepted: 26 January 2026
First Online: 17 February 2026
Declarations
:
: This study was approved by the Institutional Human Ethics Committee of the Biomedical Research Center in Bratislava, Slovakia, under reference number Myelom 001. All patient and healthy donor samples were obtained following written informed consent, consistent with the Declaration of Helsinki protocol. Clinical trial number: not applicable. This study was approved by the Institutional Animal Ethics committee of animal research of the Biomedical Research Center in Bratislava, Slovakia and State Veterinary and Food Administration of the Slovak Republic with reference number myelom. In accordance with institutional guidelines and approved protocols, in vivo experiments utilizing a MM xenograft mouse model were conducted.
: The authors declare no competing interests.
